PFE - Moderna: Counting On Pipeline Too Much

2024-02-23 16:52:40 ET

Summary

• Moderna, Inc.'s market share for the Spikevax vaccine is increasing, but the company faces a tough 2024 with expected revenue slumps.
• The new respiratory vaccine has questioned efficacy and is late to market, potentially impacting the sales potential of the company's pipeline.
• Moderna stock has already soared back above $100, though the financial outlook is murky.

Moderna, Inc. ( MRNA ) has started trending higher, as the market shifts focus to the pipeline and higher market share for the Spikevax vaccine. The biotech faces a tough 2024, with revenues set to slump again and efficacy data regarding their new respiratory vaccine questioning the sales potential of the pipeline. My investment thesis remains Bearish on MRNA stock due to the mounting losses and the primary vaccines likely to struggle hitting sales targets....

For further details see: